- Ampio Pharmaceuticals (AMPE +3.4%) reports interim results from a dose finding trial of Optina in DME.
- Ultimately, the IDRC recommended the continuation of the trial as "it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect [and] there were no significant safety concerns."
- Once the trial is complete, the company will immediately initiate an open label extension study using the determined optimum dose. (PR)
at CNBC.com (Nov 13, 2013)